This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Pharmasset Inc. (VRUS): Today's Featured Drugs Loser

Pharmasset Inc ( VRUS) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 3.6%. By the end of trading, Pharmasset Inc fell $1.44 (-1.1%) to $130.99 on heavy volume. Throughout the day, 6.8 million shares of Pharmasset Inc exchanged hands as compared to its average daily volume of 1.9 million shares. The stock ranged in price between $130.40-$132.50 after having opened the day at $132.50 as compared to the previous trading day's close of $132.43. Other company's within the Drugs industry that declined today were: Poniard Pharmaceuticals Inc ( PARDD), down 14.4%, Horizon Pharma Inc ( HZNP), down 12.7%, Marina Biotech Inc ( MRNA), down 9.1%, and AspenBio Pharma Inc ( APPY), down 8.1%.

Pharmasset, Inc., a clinical-stage pharmaceutical company, engages in discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset Inc has a market cap of $10.09 billion and is part of the health care sector. Shares are up 508% year to date as of the close of trading on Tuesday.

TheStreet Ratings rates Pharmasset as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, weak operating cash flow and deteriorating net income.

On the positive front, PROLOR Biotech Inc ( PBTH), up 21.4%, Progenics Pharmaceuticals Inc ( PGNX), up 20.9%, Amicus Therapeutics Inc ( FOLD), up 19.2%, and Sangamo BioSciences Inc ( SGMO), up 18.4%, were all gainers within the drugs industry with Johnson & Johnson ( JNJ) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Submit an article to us!
DOW 17,156.85 +24.88 0.15%
S&P 500 2,001.57 +2.59 0.13%
NASDAQ 4,562.1890 +9.43 0.21%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs